论文部分内容阅读
本院对７４８７例孕妇使用ＥＬＩＳＡ检测，发现ＣＭＶＩｇＭ阳性者１７４例，阳性率为２．３５％。对ＣＭＶＩｇＭ阳性孕妇，分为治疗组和对照组，治疗组用人脾转移因子治疗。ＣＭＶＩｇＧ阳性者重复检测ＣＭＶＩｇＧ，产后取脐血测ＣＭＶＩｇＧ及ＩｇＭ，其中７３例新生儿作了尿ＣＭＶＰＣＲ检测。脐血ＣＭＶＩｇＧ阳性率为９８．６％，ＣＭＶＩｇＭ阳性率为４．９％，新生儿尿ＣＭＶＰＣＲ阳性率为３７％。随访５５例新生儿，２２例有ＣＭＶ感染体征。结果示治疗组孕妇ＣＭＶＩｇＭ阳性转阴数明显高于对照组（Ｐ＜０．０５），同时受影响新生儿尿ＣＭＶＰＣＲ阳性率及有新生儿ＣＭＶ感染体征者均比对照组为低（Ｐ＜０．０２５及＜０．０１），故转移因子治疗妊娠期ＣＭＶ感染有一定效果。
The hospital of 7487 pregnant women using ELISA test found 174 cases of CMVIgM positive, the positive rate was 2.35%. CMVIgM-positive pregnant women, divided into treatment group and control group, the treatment group with human spleen transfer factor treatment. CMVIgG positive repeat test CMVIgG, postpartum cord blood test CMVIgG and IgM, of which 73 cases of newborns urine CMVPCR detection. The positive rate of CMVIgG in cord blood was 98.6%, the positive rate of CMVIgM was 4.9%, and the positive rate of CMV PCR in neonatal urine was 37%. Fifty-five newborns were followed up, and twenty-two with signs of CMV infection. The results showed that CMVIgM negative in treatment group was significantly higher than that in control group (P <0.05). Meanwhile, the positive rate of CMVPCR in neonates and CMV infection in neonates were lower than those in control group .025 and <0.01), so the transfer factor in the treatment of CMV infection during pregnancy have a certain effect.